Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda S
Department of Pathology, Public Health Research Institute of Kobe City, Hyogo, Japan.
Cancer Res. 1994 Jan 1;54(1):231-5.
Hepatocellular carcinoma (HCC) accumulates a mutation of the p53 gene with a common substitution of nucleotide in a particular site. It is hypothesized that infection of hepatitis B virus (HBV) or exposure to aflatoxins could induce it. In Japan, the concentration of aflatoxins in the environment is low; however, infection of HBV and/or hepatitis C virus (HCV) is frequently seen in patients with HCC. The purpose of our studies was to determine whether these hepatoviral factors influence p53 alterations. In our results, p53 abnormalities, which were composed of loss of heterozygosity (LOH) and/or point mutation, were shown in 39% of patients. We postulated that they occurred at late stages in tumor growth based on the following two results. LOH analysis on p53 showed that most of the tumor nodule consisted of two phenotypes, LOH and non-LOH cancer cells. The p53 abnormalities correlated with the grade of cancer cell atypia which advanced with tumor growth. HBV and HCV infections were identified by polymerase chain reaction using DNA extracted from cancerous and noncancerous regions of the liver. By these methods, the patients who had been infected with either HBV or HCV showed an incidence of p53 abnormalities (45%) higher than those infected by neither (13%). However, the detection rate of these viruses was lower in the HCC region (33%) than that in the noncancerous region (56%) in cases with mutated p53. The low rate of HCV detection (22%) in the HCC region with altered p53 was attributable to these different viral detection rates. There was a difference in pattern of p53 mutational changes in patients depending upon whether they were infected by HBV or by HCV. Two of three HBV-infected patients had a transversional change of nucleotide at the G:C site to T:A. However, in cases with HCV, four of eight patients had a transitional change of nucleotide of p53. These results showed that HBV and HCV infections affect carcinogenic pathways causing p53 abnormalities independently.
肝细胞癌(HCC)会积累p53基因的突变,在特定位点存在常见的核苷酸替换。据推测,乙型肝炎病毒(HBV)感染或接触黄曲霉毒素可诱发这种情况。在日本,环境中黄曲霉毒素的浓度较低;然而,HBV和/或丙型肝炎病毒(HCV)感染在HCC患者中很常见。我们研究的目的是确定这些肝病毒因素是否会影响p53改变。在我们的研究结果中,39%的患者出现了由杂合性缺失(LOH)和/或点突变组成的p53异常。基于以下两个结果,我们推测它们发生在肿瘤生长的晚期。对p53的LOH分析表明,大多数肿瘤结节由两种表型组成,即LOH和非LOH癌细胞。p53异常与随着肿瘤生长而进展的癌细胞异型性分级相关。通过使用从肝脏癌区和非癌区提取的DNA进行聚合酶链反应来鉴定HBV和HCV感染。通过这些方法,感染了HBV或HCV的患者出现p53异常的发生率(45%)高于未感染任何一种病毒的患者(13%)。然而,在p53发生突变的病例中,这些病毒在HCC区域的检测率(33%)低于非癌区域(56%)。p53改变的HCC区域中HCV的低检测率(22%)归因于这些不同的病毒检测率。根据患者是感染HBV还是HCV,p53突变变化的模式存在差异。三名HBV感染患者中有两名在G:C位点发生了核苷酸的颠换,变为T:A。然而,在HCV感染的病例中,八名患者中有四名发生了p53核苷酸的转换。这些结果表明,HBV和HCV感染分别独立地影响导致p53异常的致癌途径。